Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent
2011

New Anticancer Peptide Targets Hsp90

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): Horibe Tomohisa, Kohno Masayuki, Haramoto Mari, Ohara Koji, Kawakami Koji

Primary Institution: Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University

Hypothesis

Can a hybrid TPR peptide targeting Hsp90 serve as a selective anticancer agent?

Conclusion

The Antp-TPR peptide shows significant antitumor activity and selectively induces cancer cell death while sparing normal cells.

Supporting Evidence

  • The Antp-TPR peptide selectively killed cancer cells while leaving normal cells unharmed.
  • In vivo studies showed significant tumor suppression in mice treated with Antp-TPR peptide.
  • The peptide inhibited the interaction between Hsp90 and its cofactor, leading to cancer cell death.

Takeaway

Scientists created a special peptide that can kill cancer cells without hurting normal cells, which could help treat cancer better.

Methodology

The study involved designing a hybrid peptide, testing its effects on various cancer cell lines in vitro and in vivo using a xenograft model.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1479-5876-9-8

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication